FAQ: Aditxt Inc. Appoints Saundra Pelletier to Board of Directors and Advances in Women’s Health

Who has Aditxt Inc. appointed to its Board of Directors?

Aditxt Inc. has appointed Saundra Pelletier, CEO of Evofem Biosciences, to its Board of Directors.

What experience does Saundra Pelletier bring to Aditxt Inc.?

Saundra Pelletier brings over 30 years of global pharmaceutical experience, including launching and expanding brands across women’s reproductive health, and has led the approval and commercial growth of Phexxi(R) and the acquisition of SOLOSEC(R) at Evofem.

Why is Saundra Pelletier’s appointment significant for Aditxt Inc.?

Her appointment is significant as it strengthens Aditxt’s focus on women’s health and commercialization efforts, leveraging her extensive experience in the pharmaceutical industry and women’s reproductive health.

What are Aditxt Inc.’s current operational programs?

Aditxt currently operates two programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health.

What agreements has Aditxt Inc. entered into to advance its programs?

Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. and a merger agreement with Evofem to advance its programs in infectious diseases and women’s health, respectively.

Where can I find more information about Aditxt Inc.?

More information can be found on Aditxt’s website at www.Aditxt.com and the latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX.

What is the significance of Aditxt Inc.’s innovation platform?

Aditxt’s innovation platform is designed to democratize innovation, ensure every stakeholder’s voice is heard and valued, and empower collective progress towards discovering, developing, and deploying innovative health solutions.

What conditions must be met for the transactions with Appili and Evofem to close?

The closing of the transactions is subject to several conditions, including approval by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.